Category
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Stem Cells & Wnt
- Hippo
- Ubiquitin
- Neuronal Signaling
- NF-κB
- GPCR & G Protein
- Endocrinology & Hormones
- Transmembrane Transporters
- Metabolism
- Proteases
- Microbiology
- Others
Archives
PARP
Effect of High Cholesterol Regulation of LRP1 and RAGE on Aβ Transport Across the Blood-brain Barrier in Alzheimer's Disease
85 views | Sep 11 2021
Rui Zhou et al. found that high cholesterol decreased LRP1 expression and increased RAGE expression in cerebral microvascular endothelial cells, which led to Aβ transport disorder in the blood-brain barrier. [Read the Full Post]
Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
122 views | Aug 23 2021
Irene Paterniti et al. indicated PARP inhibitors as adjuvants for therapeutic strategy of oral cancer. [Read the Full Post]
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
120 views | Aug 23 2021
Jing Xu et al. found that veliparib and temozolomide demonstrated clinical activity in platinum-naïve BRCA-associated metastatic breast cancer with manageable toxicity at doses of veliparib well below the single-agent active dose. [Read the Full Post]
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer
97 views | Jul 20 2021
John Hang Leung et al. showed that olaparib was considered to be a cost-effective maintenance therapy for patients with recurrent platinum-sensitive ovarian cancer from the Taiwan NHIA perspective. [Read the Full Post]
Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system
76 views | Jul 08 2021
Rachel V Hatch et al. suggested that PARPi therapy was associated with numerous toxicities that were best managed through a multi-modal approach. [Read the Full Post]
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
84 views | Jul 07 2021
Md Hafiz Uddin found that KPT-8602 with or without olaparib was shown to reduce homologous recombination-regulated DNA damage response targets including BRCA1, BRCA2, CHEK1, EXO1, BLM, RAD51, LIG1, XRCC3 and RMI2. [Read the Full Post]
Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer
88 views | Jul 05 2021
Ke Shen et al. found that PARP inhibitors played an important role in killing tumor cells with defects in homologous recombination repair. [Read the Full Post]
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
80 views | Jul 04 2021
Yoichi Naito et al. showed that single-agent talazoparib was well tolerated and had preliminary antitumor activity in Japanese patients with advanced solid tumors. [Read the Full Post]
PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer
112 views | Jun 24 2021
Cheng Wu et al. provided a molecular rationale for PARPi and CDK4/6i combination therapy and revealed mechanism-based clinical trial opportunities for men with NEPC. [Read the Full Post]
High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab
92 views | May 28 2021
Chung-Han Lee et al. identified lenvatinib plus pembrolizumab as a highly active treatment strategy in RCC and reveal HLA-I diversity as a critical determinant of efficacy for this combination. [Read the Full Post]
